Aiming at the target: improved adjuvant medical therapy

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Research

Background:

• The 2007 St. Gallen Expert Panel acknowledged molecular tools for risk stratification but favored standard pathology for treatment decisions.
• Recent research highlights molecular tools' prognostic capabilities, often linked to improved proliferation quantification.
• Tumor burden remains a key factor in long-term breast cancer outcomes.

Purpose of the Study:

• To evaluate the current understanding and limitations of novel molecular tools in breast cancer risk stratification and treatment selection.
• To assess the predictive accuracy of individual markers for systemic therapy response.
• To propose future directions for developing more effective adjuvant treatment strategies.

Main Methods:

• Review and synthesis of recent findings on molecular tools in early breast cancer.
• Analysis of the prognostic and predictive performance of novel molecular assays.
• Evaluation of the challenges in validating individual predictive markers.

Main Results:

• Novel molecular tools demonstrate comparable prognostic power to standard methods, primarily through enhanced proliferation assessment.
• Current molecular tools offer suboptimal prediction of response to systemic therapies.
• Validation studies of individual predictive markers (e.g., HER-2, TOP2A, Myc, Tau) have yielded disappointing results.

Conclusions:

• The complexity of early breast cancer necessitates a shift from single-gene alterations to multi-dimensional approaches.
• Future progress in adjuvant therapy tailoring requires multi-parameter assays integrating tumor biology, disease burden, and host factors.
• Prospective biomarker discovery coupled with new drug development is crucial for advancing personalized breast cancer treatment.